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Implication for health policy/practice/research/medical education:
It has been recommended that in patients with compromised renal function (i.e. 30< eGFR <60 and 30<eGFR<45 mL/ min/1.73 
m2) and those with normal renal function and other co-morbidities, either withholding or continuing of metformin prior to 
iodinated contrast medium exposure should be based on patient’s medical condition.
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Lactic acidosis (LA) secondary to metformin administration is a rare incident with a very high 
mortality rate (≥50%). Hypoxia has been suggested to contribute to metformin-associated 
lactic acidosis (MALA) in 90% of patients developing this condition. In susceptible patients 
such as those with renal insufficiency, the level of plasma metformin is increased particularly 
after exposure to iodinated contrast media (ICM). One major concern in patients with renal 
insufficiency is to adjust the metformin dose based on the renal functional capacity prior to ICM 
examination. In this review, we assessed metformin tolerable threshold in diabetic patients with 
renal failure. We also reviewed metformin withdrawal criteria in patients with chronic kidney 
disease (CKD) exposed to intravenous ICM during angiography. Our results indicated that in 
patients with insufficient renal function (i.e. 30< estimated glomerular filtration rate(eGFR) <60 
and 30<eGFR<45 mL/min/1.73 m2), or those with acceptable renal function (eGFR ≥60 mL/
min/1.73 m2) and concomitant comorbidities, the decision to withhold or reinitiate metformin 
should be based on patient’s medical condition.
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Introduction
Lactic acidosis (LA) is a marker of inadequate tissue 
perfusion and oxygen supply. Insufficient oxygen delivery 
triggers anaerobic metabolism which finally transforms 
pyruvate to lactate (1). Metformin-associated lactic 
acidosis (MALA) is a relatively rare incident; however, the 
condition renders a very high mortality rate (2). Evidences 
from comprehensive meta-analyses and clinical studies 
have specified the efficiency and safety of metformin in 
appropriate dose. On the other hand, even elevated serum 
concentration of metformin alone is rarely indicated as a 
trigger for LA. Actually, in more than 90% of patients with 
MALA, the condition has been associated with a hypoxic 
circumstance that can prompt LA (3,4). MALA is generally 
preventable in most outpatient individuals. In fact, dose 
adjustment strategies can be effectively implemented 
to avoid MALA in patients with kidney failure, hepatic 
insufficiency, severe hypoxia, chronic heart failure, 
shock (e.g. surgery) and those who abused alcohol (5). 
Nevertheless, in vulnerable individuals with predisposing 
conditions (i.e. metformin overdose, lactate level >5 mM 
or large anion gap), severe academia (blood pH < 7.4), and 
low serum bicarbonate level (<22 mM)), MALA may be 
triggered following metformin accumulation in the body 
(6). 
The accumulation of metformin alone can explain the 
development of LA in only ≤10% of cases who mostly 
are also identified with either metformin overdose or 
acute kidney injury. The MALA is considered as the 
LA developed following metformin administration in 
patients with no obvious other predisposing and related 
diseases (7). 
Hypoxia is a serious predisposing factor and a 
prognostic indicator for MALA. Diabetes and diabetic 
nephropathy (8), renal failure (9,10), and intravascular 
iodinated contrast media (ICM) (11) decrease medullary 
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oxygenation predisposing medullary region to hypoxia. 
Actually, the intensity of hypoxia; and not the lactate or 
metformin concentrations, predicts the mortality rate in 
patients, and therefore metformin administration must 
be reconsidered in the presence of tissue hypoxia (12). 
Although a recent study has clarified no association 
between metformin administration and LA; however, this 
indication may not be applicable to susceptible individuals 
with metformin overdose (13). 
Reduced kidney function and metformin clearance are 
the most significant risk factors of MALA. In this regard, 
diabetic patients are at risk of LA following metformin 
administration. Other risk factors of MALA include 
reduced tissue oxygenation (such as in heart failure, 
hypoxemia, ICM exposure, sepsis and shock), as well 
as disturbed lactate metabolism (such as in alcoholism, 
or liver fibrosis) (Table 1) (5). Therefore, it is highly 
recommended to avoid metformin administration in 
these contraindicated conditions.
Materials and Methods
For this review, we used a variety of sources including 
PubMed, Web of Science, Embase, EBSCO, Google 
Scholar and Scopus. The search was conducted, using 
combinations of the following key words and or their 
equivalents; iodinated contrast media, lactic acidosis, 
metformin, chronic kidney disease, metformin-
associated lactic acidosis, hypoxemia, acute kidney injury, 
contrast induced nephropathy, percutaneous coronary 
intervention, nephrotoxicity and glomerular filtration 
rate.
Contrast induced nephropathy
Radiology imaging techniques such as angiography and 
computed tomography angiography (CT-angiography) 
usually provide evidence about the structure of blood 
vessels and body organs assisting in the diagnosis 
and treatment of various diseases. In most of these 
techniques, ICMs which are renal toxic agents and 
may cause complications in patients with renal disease 
are administered. In patients with pre-existing renal 
damage, particularly diabetic individuals, using ICMs in 
radiographic procedures may lead to contrast-induced 
nephropathy (CIN). CIN is defined as the elevation of 
serum creatinine ≥ 25% of the standard level within 48 
hours. ICMs may promote their nephrotoxic effects 
either indirectly by induction of renal hypoxia through 
hemodynamic alterations such as inducing renal 
vasoconstriction, and reducing vasodilatation, kidney 
blood supply, blood pressure and glomerular filtration 
rate or directly by cytotoxic effects against renal tubular 
and endothelial cells (11,14). As kidneys receive almost 
20% of cardiac output, they are particularly sensitive to 
hypoxia. Decreased kidney oxygenation, particularly 
renal medulla hypoxia, is an indicator of CIN. Applying 
ICM also increases the viscosity of kidney arterioles that 
are the main sources of renal medulla blood supply, which 
further exaggerating medullary hypoxia. These agents can 
also worsen, the endothelial dysfunction by inducing toxic 
effects toward endothelial and other renal cells (15).
Metformin-associated lactic acidosis following ICM 
induced nephropathy
By reducing kidney function, ICMs increase the risk 
of metformin accumulation predisposing to LA. 
Because of the presumed association between ICM 
and the risk of LA in patients using metformin, the 
present recommendations restrict the administration of 
metformin in patients exposing to such agents, such as 
those referred for percutaneous coronary intervention 
(PCI) (16). Nonetheless, the incidence of nephrotoxicity 
after ICM exposure is very low in individuals with normal 
serum creatinine level and renal function (17,18). The 
risk of MALA after ICM exposure is particularly escalated 
in simultaneous presence of other contraindications of 
metformin usage, particularly renal insufficiency (19). In 
accordance, multiple studies on diabetic patients treated 
with metformin have indicated that the risk of CIN is 
minimal in diabetic patients without renal disorder (3,16). 
Overall, metformin avoidance to prevent LA in patients 
who are subjected to intravenous ICM may be only 
restricted to those with abnormal renal function. 
Metformin administration in patients with chronic 
kidney disease 
There has been a point of contrary to either administer low-
dose metformin in patients with partial renal impairment 
(20) or withdraw the drug in patients with advanced 
chronic kidney disease (CKD) (21,22). There have been 
recommendations to eliminate the renal functional 
limitations on metformin administration. On the other 
hand, there have been many cases of severe side effects 
and unfavorable complications related to metformin (23). 
In fact, it has been argued that the restricting guidelines 
have likely saved thousands of lives each year from LA, 
hypoglycemia, and pancreatitis (6). 
The estimated glomerular filtration rate (eGFR) which 
is reported as mL/min/1.73 m2 is calculated based on 
serum creatinine, weight, height, age, and/or gender 
Table 1. Risk factors of metformin-associated lactic acidosis
Risk factors Examples 
Reduced metformin 
clearance
Acute kidney injury
Chronic kidney disease
Tissue hypoxia
Sepsis, shock (e.g. surgery), 
hypovolemia, heart failure, ICM 
exposure
Dysregulated lactate 
metabolism
Alcohol abuse, liver fibrosis
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(24). The eGFR has been a better indicator respective to 
serum creatinine for predicting renal insufficiency. In a 
cohort study on more than 50.000 patients with type 2 
diabetes, the predictability of different eGFRs has been 
assessed on the safety of metformin administration (25). 
The study showed, the risk of LA was ~13-fold higher in 
patients with reduced renal function treated with >2 g/d 
metformin in comparison with patients with no history 
of metformin exposure. The risk of either LA or elevated 
lactate concentration boosted in patients with severe 
renal failure (30≤eGFR <60 mL/min/1.73 m2) with the 
risk being highly escalated in patients received prolonged 
metformin therapy. 
In patients without renal problems, metformin 
improves glucose and lipid metabolisms, helps to lose 
weight, and finally postpones diabetes development. It has 
been argued that contradicting metformin administration 
in CKD patients may deprive millions of diabetic patients 
from the beneficial effects of this therapeutic agent. 
Clinical practice guidelines have suggested the thresholds 
of kidney failure and low GFR for protecting CKD 
patients from potential metformin adverse effects. Drug 
administration organizations and expert associations in 
various countries have also suggested metformin cut off 
limits to be applied in CKD patients.
The National Institute for Health and Clinical Excellence 
(NICE), American Diabetes Association (ADA), European 
Association for Study of Diabetes (EASD), Kidney 
Disease: Improving Global Outcomes (KDIGO), Royal 
Australian College of General Practitioners (RACGP), 
Japanese Society of Nephrology (JSN), National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative 
(NKF KDOQI) (6), British National Formulary (BNF) 
and Japanese Society of Nephrology (JSN) have suggested 
that metformin administration to be reconsidered at eGFR 
≤45 mL/min/1.73 m2 and discontinued at eGFR ≤30 mL/
min/1.73 m2 (26).
It should be stated that eGFR≤30 30 mL/min/1.73 
m2 has been the definite contraindication of metformin 
administration in most recommendations. Metformin 
may be continued at eGFR ≤60 mL/min/1.73 m2; however, 
renal function must be monitored approximately three 
times annually in this condition. In patients with eGFR ≤45 
mL/min per 1.73 m2, metformin dose must be readjusted 
and decreased almost to half the primary dose, since renal 
function must be evaluated approximately four times 
annually (27) (Table 2). Depending on previous medical 
history and the presence of other co-morbidities such 
as exposure to nephrotoxic ICM agents, further caution 
is required on administrating metformin in patients at 
risk of sudden decline in renal function. Maximum daily 
metformin doses of 2000 and 1000 mg have been proposed 
in patients with a eGFR of 45–60 mL/min/1.73 m2 and 
30–45 mL/min/1.73 m2 respectively (28).
Metformin administration in patients with renal 
insufficiency undergoing ICM exposure 
The development of MALA; in addition to the exposition 
to metformin, is modulated by the presence of other 
risk factors such as renal insufficiency and exposure to 
ICMs. This fact indicates the necessity for reconsidering 
metformin administration in patients with renal 
insufficiency during ICM procedure. Discontinuation 
of metformin before ICM exposure should be directed 
based on the risk of LA and baseline kidney function 
(29). In patients with compromised (i.e. 30<GFR<60 
mL/min/1.73 m2) or normal kidney function, the drug 
withdrawal must be decided considering the patients’ 
medical history. Because of the risk of CIN, monitoring 
serum-creatinine level seems necessary in all patients. 
While there has been no established relationship between 
metformin administration and either intravascular ICM 
exposure or nephrotoxicity, nevertheless, interactions 
between metformin, ICM and LA may be a hazardous 
combination leading to renal damage. The risk of 
metformin accumulation and LA is exaggerated in patients 
with CIN. The prevalence of CIN has been reported in 
the range of 0.1% to 13% with preexisting renal damage 
being an independent risk factor for this condition (30). 
One major point of concern in patients undergoing ICM 
has been the level of renal function in which metformin 
should be stopped or restarted. Table 3 presents different 
guidelines on metformin administration during ICM in 
diabetic patients.
Based on the statements presented in Tables 2 and 3, the 
followings can be guidelines concluded;
• Some guidelines (such as ACR, CAR and RANZCR) 
have not regarded the eGFR≤30 mL/min/1.73 m2 
as an absolute contraindication for metformin 
discontinuation before ICM exposure and suggested 
that the drug should be only stopped immediately 
prior to the exposure (31).
• In patients with CKD, some guidelines have 
recommended that metformin should be stopped at 
Table 2. Suggested instructions for adjusting the dose of metformin based on eGFR
eGFR (mL/min/1.73 m2) Action required
>60 Continue, check renal function annually
45-60 Continue and monitor renal function  three times per year
30-45 Reduced dose to almost half of primary dose, check renal function check four times per year
<30 Contraindicated, stop metformin administration 
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any eGFR before intravenous ICM administration (6). 
On the other hand, in patients with compromised renal 
function (i.e. either 30<eGFR<60 or 30<eGFR<45 
mL/min/1.73 m2) and those with normal kidney 
function and other co-morbidities, the decision on 
withholding and reinitiating metformin prior or at 
the time of exposure should be based on the patient’s 
medical condition (32). 
•	 It appears to be safe to continue metformin in 
patients with normal renal function (i.e. eGFR >60 
mL/min/1.73 m2) with no other comorbidities. 
•	 The, g-I/eGFR <1.42 formula is an easy and helpful 
indicator for establishing the safe iodinated contrast 
medium-dose based on the exposure eGFR values. 
Moreover, g-I/eGFR might have a close relationship 
with the development of nephropathy requiring 
dialysis as well as contrast-induced nephropathy (33).
•	 Other techniques such as magnetic resonance 
imaging, using iso- or low osmolar ICM agents at 
the minimum effective dose, and finally applying 
optimal hydration and other strategies to avoid 
CIN should be considered in at-risk patients. The 
commonly conventional practice for radiologists is to 
stop metformin administration 24 to 48 hours before 
administration of contrast media in individuals with 
an eGFR of below 60 mL/min/1.73 m2 and to renew 
its administration after testing kidney function 48 
hours subsequent the radiography (34).
Conclusion
Metformin is an efficient drug for managing various 
diseases; however, its prescription in susceptible 
individuals and contraindicated conditions (specially 
kidney insufficiency) necessitates routine monitoring. It 
is not certain in what level of renal function metformin 
should be stopped or reinitiated in patients undergoing 
ICM. Different guidelines have recommended metformin 
administration requirements in CKD patients, 
particularly those undergoing ICM procedure. It has 
been recommended that in patients with compromised 
renal function (i.e. 30< eGFR <60 and 30<eGFR<45 mL/
min/1.73 m2) and those with normal renal function and 
other comorbidities, either withholding or continuing of 
metformin prior to ICM exposure should be based on 
patient’s medical condition. 
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